Therapies Scientific Committee (TSC)

The IRDiRC’s Therapies Scientific Committee (TSC) is a multi-disciplinary, multi-stakeholder group of experts in medical research and drug development specialized in rare diseases, comprising representatives of academia, non-profit organizations, industry, regulators, patient experts, clinicians and research funders across the globe.

The TSC is devoted to pursue the therapeutic development agenda of IRDiRC, supporting the rare disease research community in developing “1000 new rare disease treatments by 2027”. The TSC publishes papers, reports and recommendations in the field, provides expert support to all IRDiRC initiatives, and runs multi-stakeholder Task Forces with internal and external experts to address defined challenges and roadblocks in rare disease drug development.

To pursue the 2027 IRDiRC goal, the key targets of the TSC in the next years will be:

  1. to support the re-definition of the development model for rare disease therapeutics enabling the best integration of the available tools and initiatives specific for rare disease, servicing both profit and non-profit developers, and
  2. to support the re-definition of the international agenda for rare disease research prioritizing areas of unsolved issues constituting roadblocks for the development of new treatment approaches.
 Name Title and Organization
Daniel O'Connor (Chair)Director, Regulatory Policy and Early Access, The Association of the British Pharmaceutical Industry (ABPI), UK
Anneliene Jonker (Vice-Chair)Assistant Professor, Rare Diseases Therapeutic Innovation, University of Twente & Scientific Director, Duchenne Parent Project, The Netherlands
Diana KwastNursing Scientist - PhD candidate Multimorbidity/Rare Diseases at the University of Groningen, EUPATI Fellow (IT) and Patient Representative EURORDIS project Mental Health and Wellbeing, The Netherlands
Emilio J.A. RoldanScientific Director of Qualix DoT, Argentina
Janet MaynardDirector of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine at U.S. Food and Drug Administration, USA
Maria Cavaller BellaubiPatient Engagement & Therapeutic Development Director, EURORDIS - Rare Diseases Europe, Spain
Marjon PasmooijScience Programme Manager at Medicines Evaluation Board (CBG/MEB), University Medical Center Groningen, The Netherlands
Martina KawomeOphtalmologist, Department of Ophtalmology, College of Health Sciences, Harare, Zimbabwe
Michelle FarrarProfessor and Paediatric Neurologist at School of Clinical Medicine/Sydney Children's Hospital, Australia
Rajesh KrishnaDistinguished Scientist and Global Lead, Rare Diseases Center of Excellence, Certara, USA
Thomas MorelResearch Fellow at KU Leuven/Director, Global Patient-Centred Outcomes Research; Policy at UCB Biopharma, Belgium​
Trudy NyakambangweFounder at Child And Youth Care Zimbabwe, Zimbabwe

Related link :